文献速递基础与转化研究临床试验与 GCP

伊匹木单抗治疗前列腺癌的新抗原应答与免疫相关因素及良好结局

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
PubMed 文献 · Sci Transl Med · 2020-01-01

在30例转移性去势抵抗性前列腺癌患者中开展伊匹木单抗临床试验,按生存和进展时间分为有利组(n=9)与不利组(n=10)。有利组患者具有高瘤内CD8 T细胞密度、IFN-γ应答基因特征和/或抗原特异性T细胞应答,2例低TMB患者出现针对独特新抗原的T细胞应答。有利组6/9例存活(生存33至54个月),不利组10例全部死亡(生存0.6至10.3个月)。

要点

  • 低TMB前列腺癌患者经伊匹木单抗治疗仍可诱导新抗原特异性T细胞应答。
  • 有利组具高瘤内CD8 T细胞密度、IFN-γ基因特征和/或抗原特异性T细胞应答。
  • 免疫效应T细胞相关因素与转移性前列腺癌患者ICB获益相关。

核心结论

  • 在转移性去势抵抗性前列腺癌患者中,与效应T细胞应答相关的免疫相关因素见于从ICB获益的患者。

研究设计与样本

  • 在30例转移性去势抵抗性前列腺癌患者中开展伊匹木单抗临床试验。
  • 按生存和进展时间识别出有利组(n=9)与不利组(n=10)两个队列。

主要发现

  • 有利组患者具有高瘤内CD8 T细胞密度和IFN-γ应答基因特征和/或抗原特异性T细胞应答。
  • 2例TMB相对较低的患者出现针对独特新抗原的T细胞应答。
  • 有利组9例中6例在分析时仍存活,生存33至54个月。
  • 不利组10例全部死于疾病,生存0.6至10.3个月。

临床怎么用

  • 对低TMB的转移性去势抵抗性前列腺癌,可关注瘤内CD8 T细胞密度、IFN-γ应答基因特征及抗原特异性T细胞应答等免疫相关因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumors with high mutational burden (TMB) tend to be responsive to immune checkpoint blockade (ICB) because there are neoantigens available for targeting by reinvigorated T cells, whereas those with low TMB demonstrate limited clinical responses. To determine whether antigen-specific T cell responses can be elicited after treatment with ICB in cancers that have a low TMB, we conducted a clinical trial with ipilimumab in 30 patients with metastatic castration-resistant prostate cancer. We identified two distinct cohorts by survival and progression times: "favorable" (n = 9) and "unfavorable" (n = 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020. PMID: 32238575. doi:10.1126/scitranslmed.aaz3577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。